Contact Us

Customers and personnel or representatives of Cardinal Health may contact the Call Center by one or a combination of the following communication methods:

For domestic inquiries:
1. Telephone (USA): 1.800.476.5270
2. Mail: Cardinal Health, 7200 Cardinal Place, Dublin, Ohio 43017

Corporate Headquarters
Cardinal Health
7000 Cardinal Place
Dublin, OH 43017
(p) 614.757.5000
nuclearpharmacy@cardinalhealth.com

Pharmacovigilance/Adverse Event Reporting
To report suspected adverse reactions, contact Cardinal Health at
1.800.618.2768 or FDA at 1.800.FDA.1088 or
www.fda.gov/medwatch.

Medical Drug Information
1.800.476.5270
npsmedicalinfo@cardinalhealth.com

Safety Information
npssafety@cardinalhealth.com

Request Information

Thank you for your interest in LYMPHOSEEK®. Please submit your inquiries by filling in the form below or call us at: 1.800.476.5270.

*
*
 
*
*
 

*Required Fields


*Indication

LYMPHOSEEK is a radioactive diagnostic agent indicated with or without scintigraphic imaging for:

  • Lymphatic mapping using a handheld gamma counter to locate lymph nodes draining a primary tumor site in patients with solid tumors for which this procedure is a component of intraoperative management.
  • Guiding sentinel lymph node biopsy using a handheld gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity, breast cancer or melanoma.

 

Important Safety Information

In clinical trials with LYMPHOSEEK, no serious hypersensitivity reactions were reported, however LYMPHOSEEK may pose a risk of such reactions due to its chemical similarity to dextran. Serious hypersensitivity reactions have been associated with dextran and modified forms of dextran (such as iron dextran drugs).

Prior to the administration of LYMPHOSEEK, patients should be asked about previous hypersensitivity reactions to drugs, in particular dextran and modified forms of dextran. Resuscitation equipment and trained personnel should be available at the time of LYMPHOSEEK administration, and patients observed for signs or symptoms of hypersensitivity following injection.

Any radiation-emitting product may increase the risk for cancer. Adhere to dose recommendations and ensure safe handling to minimize the risk for excessive radiation exposure to patients or health care workers.

In clinical trials, no patients experienced serious adverse reactions and the most common adverse reactions were injection site irritation and/or pain (<1%).
Please see full Prescribing Information.

To report suspected adverse reactions, contact Cardinal Health at 1.800.618.2768 or FDA at 1.800.FDA.1088 or www.fda.gov/medwatch.

The information on this web site is intended for use only by healthcare professionals in the United States.